title: Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
abstract: We examined the feasibility of achieving a rapid response in patients with previously untreated multiple myeloma by administering vincristine 0.4 mg and doxorubicin 9 mg/m2 as a rapid intravenous infusion for 4 d together with intermittent high-dose dexamethasone 40 mg (VAD) for remission induction treatment in patients who were scheduled to receive high-dose therapy. 139 patients (86 male, 53 female; median age 53 years, range 32-65 years; Durie & Salmon stage IIA: 42, IIB: one, IIIA: 89, IIIB: seven) were included in a prospective multicentre study in which VAD was administered as remission induction treatment and was followed by intensified treatment. The response was evaluated according to the criteria of the Eastern Cooperative Oncology Group (ECOG). The results of treatment were evaluable in 134 patients. Five patients died before evaluation. 86 patients (62%) achieved a partial response (PR) and seven patients (5%) achieved a complete response (CR), which equates to a response rate of 67%. The main side-effect was mild neurotoxicity, which was observed in 18% of the patients. Fever or infections were reported in 27% of the patients. VAD administered as an outpatient regimen, based on rapid intravenous infusion, is an effective induction regimen for untreated myeloma with a 67% response rate and acceptable toxicity.
authors.affiliation: University Hospital Rotterdam and University Hospital Utrecht for the Belgium-Dutch Haematology-Oncology Group (HOVON), The Netherlands. segeren@haed.azr.nl
authors.forename: C M
authors.initials: CM
authors.lastname: Segeren
authors.forename: P
authors.initials: P
authors.lastname: Sonneveld
authors.forename: B
authors.initials: B
authors.lastname: van der Holt
authors.forename: J W
authors.initials: JW
authors.lastname: Baars
authors.forename: D H
authors.initials: DH
authors.lastname: Biesma
authors.forename: J J
authors.initials: JJ
authors.lastname: Cornellissen
authors.forename: A J
authors.initials: AJ
authors.lastname: Croockewit
authors.forename: A W
authors.initials: AW
authors.lastname: Dekker
authors.forename: W E
authors.initials: WE
authors.lastname: Fibbe
authors.forename: B
authors.initials: B
authors.lastname: Löwenberg
authors.forename: M
authors.initials: M
authors.lastname: van Marwijk Kooy
authors.forename: M H
authors.initials: MH
authors.lastname: van Oers
authors.forename: D J
authors.initials: DJ
authors.lastname: Richel
authors.forename: H C
authors.initials: HC
authors.lastname: Schouten
authors.forename: E
authors.initials: E
authors.lastname: Vellenga
authors.forename: G E
authors.initials: GE
authors.lastname: Verhoef
authors.forename: P W
authors.initials: PW
authors.lastname: Wijermans
authors.forename: S
authors.initials: S
authors.lastname: Wittebol
authors.forename: H M
authors.initials: HM
authors.lastname: Lokhorst
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011446:Prospective Studies; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin